• Explore /
  • Poster
  • / Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.

Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.

Abstract Poster

Authors

null

Martin D. Berger

Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

Martin D. Berger , Sebastian Stintzing , Volker Heinemann , Shu Cao , Yuji Miyamoto , Mitsukuni Suenaga , Diana L. Hanna , Shivani Soni , Alberto Puccini , Ryuma Tokunaga , Madiha Naseem , Francesca Battaglin , Wu Zhang , Chiara Cremolini , Alfredo Falcone , Fotios Loupakis , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 558)

DOI

10.1200/JCO.2019.37.4_suppl.558

Abstract #

558

Poster Bd #

G1

Abstract Disclosures

Similar Posters

First Author: Martin D. Berger

First Author: Francesca Battaglin

First Author: Francesca Battaglin

First Author: Madiha Naseem